SOLUTIONS FOR VIROLOGY AND VACCINE DISCOVERY

Enabling the discovery of vaccines and antiviral therapeutics against SARS-CoV-2, dengue, Zika, and other viruses

Reporter Viruses

Epitope Mapping
MAb Specificity Testing

The most extensive catalog of Reporter Virus Particles (RVPs)

Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation

Our extensive catalog of SARS-CoV-2 variants manufactured with rigorous quality control can help your discovery program meet FDA guidances for COVID-19 vaccines and therapeutics

SARS-CoV-2 and Emergent Variant RVPs

Catalog No. (G/L*)
SARS-CoV-2 / Variant
WHO
Mutations
D614G
RVP-701
Wuhan-Hu-1
———
Reference seq (GenBank QHD43416.1)
No
RVP-702
D614G B.1, 20A
———
D614G
Yes
RVP-727
Indian variant B.1.617, RBD mutations only (“double mutant”)
———
L452R, E484Q
Yes
RVP-730
Indian variant B.1.617.1
Kappa
G142D, E154K, L452R, E484Q, P681R, Q1071H
Yes
RVP-763
Indian variant B.1.617.2
Delta
T19R, G142D, del156/157, R158G, L452R, T478K, P681R, D950N
Yes
RVP-765
DELTA PLUS (Delta + K417N) B.1.617.2.1
———
T19R, G142D, del156-157, R158G, K417N, L452R, T478K, P681R, D950N
Yes
RVP-766
C.37
Lambda
G75V, T76I, R246N, del247-253, L452Q, F490S, T859N
Yes
RVP-736
Brazilian variant P.2
Zeta
E484K, V1176F, D614G
Yes
RVP-728
UK/Nigerian variant B.1.1.318, 20B/484K
———
T95I, ΔY144, E484K, P681H, D796H
Yes
RVP-735
Bengal variant B.1.618
———
ΔY145-H146, E484K, D614G
Yes
RVP-706
UK variant B.1.1.7, 20I/501Y.V1
Alpha
ΔH69/V70, ΔY144, N501Y, A570D, P681H, T716I, S982A, D1118H
Yes
RVP-717
UK variant B.1.1.7 with E484K
———
ΔH69/V70, ΔY144, E484K, N501Y, A570D, P681H, T716I, S982A, D1118H
Yes
RVP-724
South African variant Δ3 B.1.351, 20H/501Y.V2
Beta
L18F, D80A, D215G, ΔL242/A243/L244, R246I, K417N, N501Y, E484K, A701V
Yes
RVP-715
South African variant B.1.351, RBD mutations only
———
K417N, E484K, N501Y
Yes
RVP-726
New York variant B.1.526, 20C/484K
Iota
L5F, T95I, D253G, E484K, A701V
Yes
RVP-708
Brazilian variant P.1, 20J/501Y.V3
Gamma
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, V1176F
Yes
RVP-723
Nigerian/European variant B.1.525, 20A/439K
Eta
Q52R, ΔH69/V70, ΔY144, E484K, Q677H, F888L
Yes
RVP-713
Californian variant B.1.427/B.1.429, 20C/452R
Epsilon
S13I, W152C, L452R
Yes

*All RVPs are available with a GFP (G) or luciferase (L) reporter. Please add G/L to the catalog number when ordering to indicate the preferred reporter gene.

Custom SARS-CoV-2 RVP variants and RVPs from our library of 1,200 alanine spike mutants are available upon request. Please contact us for pricing.

Learn more about accelerating COVID-19 R&D programs in accordance with FDA guidances

 

More SARS Variant RVPs

Catalog No. (G/L)
SARS-CoV-2 RVPs / Variants
WHO
Mutations
D614G
RVP-710
US/Ohio strain, N501Y 20G/501Y
———
N501Y
Yes
RVP-711
S477N (Australian/European variant)**
———
S477N
Yes
RVP-712
COHD15, US/Ohio variant
———
Q677H, L938F
Yes
RVP-718
Robin* 20G/677H
———
Q677H
Yes
RVP-719
Pelican* 20G/677P
———
Q677P
Yes
RVP-721
Quail* 20B/677H
———
Q677H, T732S
Yes
RVP-722
Mockingbird* 20A/677H
———
G142S, E180V, Q677H
Yes
RVP-709
E484K
———
E484K
Yes
RVP-703
N439K
———
N439K
No
RVP-704
N439K/D614G 20A/439K
———
N439K
Yes
RVP-705
Danish mink “cluster 5”
———
ΔH69/V70, Y453F, I692V, M1229I
No
RVP-725
US variant N679S***
———
N679S
Yes
RVP-707
South African variant B.1.351, 20C/501Y.V2
———
L18F, D80A, D215G, L242H, R246I, K417N, N501Y, E484K, A701V
Yes
RVP-714
South African variant Δ2 B.1.351, 20H/501Y.V2
———
L18F, D80A, D215G, ΔL242/A243, R246I, K417N, N501Y, E484K, A701V
Yes
RVP-801
SARS-CoV-1 Urbani
———
N/A
N/A
RVP-901
MERS-CoV HCoV-EMC (GFP only)
———
N/A
N/A

* Described in Hodcroft et al., 2021

** Described in Hodcroft et al., 2020

***Identified in a newborn with high viral load (LoTempio et al., 2021)

See RVP application note

RVPs Coming Soon​

Catalog No. (G/L)
SARS-CoV-2 RVPs / Variants
WHO
Mutations
D614G
RVP-767
Columbia, B.1.621
Mu
T95I, Y144T, Y145S, ins146N, R346K,E484K, N501Y, P681H
Yes

Negative Control RVPs

Catalog No. (G/L)
RVP
Strain
RVP-1002
VSV with MLV core
Indiana

VSV with MLV RVPs can be used as a neutralization control with our transgenic ACE2 cells.

Cell Lines

Catalog No.
Transgenes
Expression
Clonality
Origin Cell Line
C-HA102
hsACE2
Stable
Monoclonal
HEK 293T

Flavivirus RVPS

Catalog No. (G/L)
Virus
Strain
RVP-101
Dengue Virus 1
WestPac
RVP-201
Dengue Virus 2
S16803
RVP-301
Dengue Virus 3
CH53489
RVP-401
Dengue Virus 4
TVP360
RVP-601
Zika Virus
SPH2015

Integral Molecular’s RVPs are produced under stringent quality-controlled conditions

With two decades of virology experience, Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials

See RVP application notes

Frequently Asked Questions

Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery and antibody discovery against viral targets.

RVPs incorporate virus-specific prM/E proteins and are antigenically equivalent to live wildtype viruses. They contain a modified RNA genome so they are safe and replication incompetent.

RVPs are useful for high-throughput infectivity and neutralization assays. They are an efficient alternative to plaque assays.

Luciferase or GFP is used for quantitative read out.

Integral Molecular does not work with any live viruses capable of causing infectious disease. We have developed Reporter Virus Particles (RVPs) to enable scientists to study viral components without the risk of exposure to viruses or the spread of contagious illnesses.

Ready To Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.

Or call (215) 966-6061